SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 4 — Sick Visit — Pablo Neruda — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientPablo Neruda
Date of birth1904-07-12
IdentifiersMRN HR-ML051-SYN-TD; SSN (made up) 000-51-2976
Document date1971-08-10
AuthorMarisol Fairweather-Diaz, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Itchy rash for four days. [S]

History of Present Illness

Mr. Neruda, a 67-year-old man with metastatic hormone-sensitive prostate cancer on leuprolide and apalutamide, now in the third week of radiotherapy to the prostate, called the clinic and was seen the same day, with a professional Spanish interpreter. Four days ago an itchy red rash appeared on his chest and spread to his back and upper arms. He has taken apalutamide for eight weeks. He started no other new medicine, soap or detergent. He has no fever, sore mouth, sore or red eyes, blisters, peeling, swelling of the face, or joint pain. The skin over the radiotherapy field on his lower abdomen is not affected. The itch keeps him awake for part of the night, but he is still writing every morning. [S]

ElementDetail
OnsetFour days ago, eight weeks after starting apalutamide
LocationChest, back and upper arms; face, palms, soles and the radiotherapy field spared
CharacterRed, flat and slightly raised spots joining into patches; itchy
Associated signs and symptomsDenies fever, mouth or eye sores, blisters, peeling and facial swelling

Review of Systems

SystemResultFinding
ConstitutionalNegativeNo fever or chills; tiredness from radiotherapy, unchanged
IntegumentaryPositiveItchy rash on the trunk and upper arms; no blisters or peeling
EyesNegativeNo redness, pain or discharge
Ears, nose, mouth, and throatNegativeNo mouth sores or sore throat
MusculoskeletalNegativeNo joint pain or swelling; no bone pain
GenitourinaryPositiveUrinary frequency during radiotherapy, as expected; no burning or blood

6 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Amlodipine 5 mg oral tablet, one tablet dailyOne tablet dailyOral route1966-04-06 to 1971-07-13completedS
Amlodipine 10 mg oral tablet, one tablet dailyOne tablet dailyOral route1971-07-13activeS
Acetaminophen 500 mg oral tablet, two tablets (1000 mg) up to three times daily as needed for bone painTwo tablets up to three times daily as neededOral route1971-06-01 to 1971-09-14completedS
Apalutamide 240 mg oral tablet, one tablet once daily, swallowed whole, with or without foodOne tablet once dailyOral route1971-06-15activeS
Leuprolide acetate 22.5 mg injection (three-month depot), intramuscular, every twelve weeksOne injection every twelve weeksIntramuscular route1971-06-22activeS
Cholecalciferol (vitamin D3) 1945 units (0.05 mg) oral tablet, one tablet dailyOne tablet dailyOral route1971-06-15activeS
Denosumab 60 mg/mL prefilled syringe, 60 mg subcutaneously every six months, for high fracture risk on androgen deprivationOne injection every six monthsSubcutaneous route1971-07-13activeS
Triamcinolone acetonide 0.1% cream, apply a thin layer to the rash twice daily for two weeks (not the face or groin)Twice daily for two weeksTopical route1971-08-10 to 1971-08-24completedS
Cetirizine 10 mg oral tablet, one tablet daily for itchOne tablet dailyOral route1971-08-10 to 1971-08-31completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1971-08-10Body height178cmS
1971-08-10Body weight93kgS
1971-08-10Body mass index (BMI) [Ratio]29.4kg/m2S
1971-08-10Systolic blood pressure136mm[Hg]S
1971-08-10Diastolic blood pressure82mm[Hg]S
1971-08-10Heart rate80/minS
1971-08-10Respiratory rate14/minS
1971-08-10Body temperature36.8CelS
1971-08-10Oxygen saturation in Arterial blood by Pulse oximetry97%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1971-08-10Leukocytes [#/volume] in Blood by Automated count6.810*3/uL4-11 10*3/uLNormalS
1971-08-10Eosinophils [#/volume] in Blood by Automated count0.310*3/uL0-0.5 10*3/uLNormalS
1971-08-10Creatinine [Mass/volume] in Serum or Plasma0.97mg/dL0.74-1.35 mg/dLNormalS
1971-08-10Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1966)/1.73 sq M86mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
1971-08-10Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma27U/L7-55 U/LNormalS
1971-08-10Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma26U/L8-48 U/LNormalS

Physical Exam

Vital signs recorded on 1971-08-10; see the Vital Signs section. [S]

SystemFinding
GeneralWell, comfortable; temperature 36.8, blood pressure 136/82, pulse 80
SkinBlanching erythematous macules and papules, merging into patches, over the chest, abdomen above the radiotherapy field, back and upper arms, about 20 percent of body surface; no vesicles, bullae, target lesions, skin pain or Nikolsky sign; face, palms, soles and genitals clear
EyesConjunctivae clear
MouthMucosa moist and intact; no ulcers
Lymph nodesNo cervical, axillary or inguinal lymphadenopathy
AbdomenSoft and non-tender; no liver enlargement

Problems

ProblemClinical statusVerificationCodeProvenance
Urinary frequency, weak stream and nocturia for four months, with right hip and low back pain for six weeks, a hard nodular prostate and a raised PSA; suspected prostate cancer, to be confirmedresolvedconfirmed R97.20S — Synthetic presenting problem, resolved at the second visit when biopsy and staging established metastatic prostate cancer.
Adenocarcinoma of the prostate, Grade Group 4 (Gleason 4+4), cT3a N1 M1b, de novo metastatic hormone-sensitive disease, low volume by conventional imaging (two bone metastases, in the right ilium and L5, and two pelvic lymph nodes; no visceral disease); synthetic modern detail linked to his documented prostate cancer of 1916activeconfirmed C61S — Synthetic grade, stage, extent and PSA; the prostate cancer and the operation in France in 1971 are documented (D), and no stage, grade or treatment detail was found in the sources read.
Bone metastases from prostate cancer: right iliac wing (painful) and L5 vertebral body; no cord compressionactiveconfirmed C79.51S — Synthetic metastatic sites.
Pelvic lymph node metastases: right external iliac and right obturator nodesactiveconfirmed C77.5S — Synthetic nodal disease.
Hormone-sensitive prostate canceractiveconfirmed Z19.1S — Synthetic status in the modern episode.
Continuous androgen deprivation (leuprolide) with apalutamide, with monitoring of testosterone, PSA, thyroid function, blood pressure, glucose and lipids, bone health, rash, falls, hot flashes, sexual health, mood and cognitionactiveconfirmed Z79.899S — Synthetic treatment plan; Z79.899 is used because ICD-10-CM has no specific code for GnRH agonist therapy.
Essential hypertension for five years, on amlodipineactiveconfirmed I10S — Synthetic comorbidity, relevant to cardiovascular risk on androgen deprivation; not a claim about his real blood pressure.
Vitamin D insufficiency (25-hydroxyvitamin D 22 ng/mL)activeconfirmed E55.9S — Synthetic finding at intake, addressed at the second visit.
Low bone mass (femoral neck T-score -2.1, L1 to L4 -1.4) with a ten-year hip fracture risk above 3% (FRAX, with androgen deprivation counted as a cause of secondary osteoporosis)activeconfirmed M85.89S — Synthetic bone-health finding on the DXA before androgen deprivation.
Prediabetes (hemoglobin A1c 5.9%)activeconfirmed R73.03S — Synthetic metabolic finding at intake, relevant to androgen deprivation.
Maculopapular drug rash from apalutamide, grade 2 (about 20 percent of body surface, trunk and upper arms), eight weeks into treatment; no mucosal involvement, blistering, fever, eosinophilia or liver involvement; settled on topical steroid and an antihistamine without stopping apalutamideactiveconfirmed L27.0S — Synthetic intercurrent problem at an unscheduled visit; a known effect of apalutamide, not a historical claim.

Assessment and Plan

Guideline basis: NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer (2026); ERLEADA (apalutamide) tablets: prescribing information (2026)

Follow-up: Nurse telephone call in three days, with a photograph of the rash through the patient portal if he wishes. Three-month review in five weeks. Same-day review for any of the warning signs. Next scheduled visit 1971-09-14: three-month review: PSA and testosterone, thyroid function, blood count and chemistry, glucose, radiotherapy effects, the rash, the second leuprolide injection, and plans for the year. [S]